A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)

Cannot have received: antibody-drug conjugate

Exception: with TOP I inhibitors as a toxin

Prior treatment with an ADC drug with TOP I inhibitors as a toxin

Cannot have received: systemic antitumor regimen

Received any previous systemic antitumor regimen for solid tumors such as recurrent or metastatic head and neck squamous cell carcinoma

Cannot have received: immunotherapy

Exception: if developed ≥ grade 3 irAE or ≥ grade 2 immune-related myocarditis

Had received immunotherapy and developed ≥ grade 3 irAE or ≥ grade 2 immune-related myocarditis

Cannot have received: anti-tumor treatment

Exception: within four weeks or five half-life before first delivery

Before the first delivery within four weeks or five half-life used anti-tumor treatment

Cannot have received: palliative radiotherapy

Exception: within 2 weeks before the first dose

Palliative radiotherapy was given within 2 weeks before the first dose